In the panel discussion for the fourth quarter of 2025, Inify’s CEO Fredrik Palm, Product Manager Kristian Eurén and the panel lead Ole Eikland discuss key highlights of the period.
Sales in the fourth quarter increased by 33% compared to the same period last year and by 66% for the full year. During the quarter, Inify gained access to its new facilities in Milton Park, UK. Installation of the laboratory equipment has commenced, and Inify has applied for the required regulatory permits to start clinical routine diagnostics. The verification of the full system is planned shortly.
Initially, the newly built laboratory in the UK will focus on prostate cancer diagnostics, gradually expanding to include gastrointestinal samples. “There is a strong awareness in the UK about the challenges they are facing to meet the ambitious targets they have in the diagnostics and patient pathways. And we are experiencing a clear interest in our services that are addressing all those challenges sustainably”, says Fredrik Palm.
In September, Inify launched its gastrointestinal service in Sweden, successfully receiving its first samples the same month. One of the key issues in the gastrointestinal field is long waiting times, sometimes months. “I think the reason is that in healthcare today, the focus is always cancer. That’s always high priority samples. So, in gastrointestinal diseases, there are a lot of non-cancer questions, and they tend to be low priority. So, having a guaranteed answer in ten days means that they can schedule the follow-up with the patient already when they do the examination, says Kristian Eurén.
Listen to the panel discussion to hear the full interview and firsthand feedback from our customers on the gastrointestinal service and more here.